{"id":7657,"date":"2020-01-13T06:36:57","date_gmt":"2020-01-13T06:36:57","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\/"},"modified":"2020-01-13T06:36:57","modified_gmt":"2020-01-13T06:36:57","slug":"nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\/","title":{"rendered":"Nicox : Approbation de VYZULTA au Mexique par son partenaire licenci\u00e9"},"content":{"rendered":"<p>Sophia Antipolis, France<\/p>\n<p><strong>Nicox SA<\/strong> (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9, Bausch + Lomb, a re\u00e7u l\u2019approbation de mise sur le march\u00e9 au Mexique de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024%.<\/p>\n<p>L\u2019approbation au Mexique fait suite aux approbations de VYZULTA aux Etats-Unis et au Canada. VYZULTA est indiqu\u00e9 pour la r\u00e9duction de la pression intraoculaire (PIO) chez les patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire.<\/p>\n<p><strong>Gavin Spencer, <em>Chief Business Officer<\/em> de Nicox a d\u00e9clar\u00e9<\/strong> : \u201c <em>VYZULTA est maintenant approuv\u00e9 dans trois principaux march\u00e9s. Cette approbation contribuera aux sources de revenus de Nicox et confirme la valorisation de nos produits en partenariat, en compl\u00e9ment de nos propres activit\u00e9s de d\u00e9veloppement, renforc\u00e9s par notre r\u00e9cent partenariat pour ZERVIATE en Cor\u00e9e du Sud et le lancement commercial \u00e0 venir de ZERVIATE aux \u00c9tats-Unis par notre partenaire Eyevance<\/em>.\u201d<\/p>\n<p>Nicox re\u00e7oit des redevances nettes croissantes de 6% \u00e0 12% sur les ventes mondiales de VYZULTA ainsi que de futurs paiements d\u2019\u00e9tape pouvant atteindre un montant de 150 millions de dollars.<\/p>\n<p>Bausch + Lomb est un leader mondial de la sant\u00e9 oculaire, filiale de Bausch Health Companies Inc. (NYSE\/TSX: BHC).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9, Bausch + Lomb, a re\u00e7u l\u2019approbation de mise sur le march\u00e9 au Mexique de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024%. L\u2019approbation au Mexique fait suite aux approbations de VYZULTA aux [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-7657","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox : Approbation de VYZULTA au Mexique par son partenaire licenci\u00e9 - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox : Approbation de VYZULTA au Mexique par son partenaire licenci\u00e9 - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9, Bausch + Lomb, a re\u00e7u l\u2019approbation de mise sur le march\u00e9 au Mexique de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024%. L\u2019approbation au Mexique fait suite aux approbations de VYZULTA aux [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2020-01-13T06:36:57+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox : Approbation de VYZULTA au Mexique par son partenaire licenci\u00e9\",\"datePublished\":\"2020-01-13T06:36:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\\\/\"},\"wordCount\":221,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\\\/\",\"name\":\"Nicox : Approbation de VYZULTA au Mexique par son partenaire licenci\u00e9 - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-01-13T06:36:57+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox : Approbation de VYZULTA au Mexique par son partenaire licenci\u00e9 - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox : Approbation de VYZULTA au Mexique par son partenaire licenci\u00e9 - Nicox","og_description":"Sophia Antipolis, France Nicox SA (Euronext Paris : FR0013018124, COX, \u00e9ligible PEA-PME), une soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui que son partenaire licenci\u00e9, Bausch + Lomb, a re\u00e7u l\u2019approbation de mise sur le march\u00e9 au Mexique de VYZULTA\u00ae (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024%. L\u2019approbation au Mexique fait suite aux approbations de VYZULTA aux [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\/","og_site_name":"Nicox","article_published_time":"2020-01-13T06:36:57+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\/"},"author":{"name":"","@id":""},"headline":"Nicox : Approbation de VYZULTA au Mexique par son partenaire licenci\u00e9","datePublished":"2020-01-13T06:36:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\/"},"wordCount":221,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\/","url":"https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\/","name":"Nicox : Approbation de VYZULTA au Mexique par son partenaire licenci\u00e9 - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2020-01-13T06:36:57+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-approbation-de-vyzulta-au-mexique-par-son-partenaire-licencie\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7657"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7657\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}